Clinical trial for Peripheral Neuropathy Due to Chemotherapy
Official title Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy
ClinicalTrials.gov ID: NCT07095998
What this study is testing
- What it's testing
- This study aims to look at nerve excitability in people with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.
- Participants must have adequate hematologic parameters to allow chemotherapy.
You likely can't join if
- Pre-existing peripheral neuropathy;
- Family history of a genetic/familial neuropathy;
- Any contraindication for treatment with cisplatin as determined by their primary oncologist;
- Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
- Patients with cardiac or spinal stimulating devices;
- Women who are pregnant or breastfeeding;
See the full eligibility criteria
- Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.
- Participants must have adequate hematologic parameters to allow chemotherapy.
- Pre-existing peripheral neuropathy;
- Family history of a genetic/familial neuropathy;
- Any contraindication for treatment with cisplatin as determined by their primary oncologist;
- Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
- Patients with cardiac or spinal stimulating devices;
- Women who are pregnant or breastfeeding;
- Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;
- Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;
- Adults age ≥ 18 with a diagnosis of cis-PN.
- Pre-existing peripheral neuropathy;
- Family history of a genetic/familiar neuropathy;
- History of cisplatin-based regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;
- Patients with cardiac or spinal stimulating devices;
- Women who are pregnant or breastfeeding;
- Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;
- Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;
- Patients not considered to be able to comply with the protocol.
The study team makes the final eligibility decision.
Where it is enrolling
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Boston, Massachusetts, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.